CC BY-NC-ND 4.0 · Asian J Neurosurg 2024; 19(01): 058-062
DOI: 10.1055/s-0043-1771323
Original Article

The Accuracy of the S100B Protein Biomarker in the Prognosis of Patients with Acute Spinal Cord Injury

1   Department of Neurosurgery, Orthopedic Research Center, Mazandaran University of Medical Science, Sari, Iran
Saeed Abediankenari
2   Immunogenetics Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Saeed Ehteshami
3   Department of neurosurgery, Orthopedic Research Center, Mazandaran University of Medical Science, Sari, Iran
Abbas Alipour
4   Thalassemia Research Center, Mazandaran University of Medical Science, Sari, Iran
Hassan Shayan Majd
5   Department of Neurosurgery, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Science, Sari, Iran
5   Department of Neurosurgery, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Science, Sari, Iran
Leila Asadian
6   Department of Emergency Medicine, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
› Author Affiliations


Introduction The role of some biomarkers such as S100 beta (S100B) has been somewhat known in determining the severity of primary acute spinal cord injury (SCI), and today, it has been the basis of various relevant studies. Therefore, this study estimates the S100B level in serum and cerebrospinal fluid (CSF) in patients with spinal injuries.

Methods This was a descriptive-analytic study. In this study, 31 patients with acute SCI referred to Sari Imam Khomeini Hospital, Iran, were recruited. Patients were divided into two groups of complete and incomplete SCI according to the American Spinal Injury Association (ASIA). The S100B concentrations in serum and CSF levels were compared between the two groups.

Result There was only significant positive correlation between S100B CSF concentration and complete SCI based on the ASIA criterion, meaning that in cases of complete SCI the S100B CSF concentration was significantly increased correlation coefficient (CC) (cc = 0.529 and p = 0.002). Based on the results of serum S100B protein concentration, 14.70 ng/dL with a sensitivity of 66.7% and specificity of 55% was determined as cutoff for complete SCI. Also, about the CSF S100B protein level variable, concentration of 342.18 ng/dL with 100% sensitivity and 64% specificity was determined as cutoff for complete injury.

Conclusion The results of this unique study have shown that S100B were useful markers for predicting the prognosis of patients with acute SCI and cutoff points determined for serum and especially CSF concentrations can differentiate complete and incomplete SCI.

Publication History

Article published online:
16 April 2024

© 2024. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J. Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology 2010; 34 (03) 184-192 , discussion 192
  • 2 Rodrigues LF, Moura-Neto V. E Spohr TCLS. Biomarkers in spinal cord injury: from prognosis to treatment. Mol Neurobiol 2018; 55 (08) 6436-6448
  • 3 WHO. Spinal cord injury. November 19, 2013. Accessed June 23, 2023 at:
  • 4 Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point. Resuscitation 2009; 80 (03) 341-345
  • 5 Fakharian E, Tabesh H, Masoud SA. An epidemiologic study on spinal injury in Kashan. Gilan Univ J 2006; 13 (49) 79-85
  • 6 Ydens E, Palmers I, Hendrix S, Somers V. The next generation of biomarker research in spinal cord injury. Mol Neurobiol 2017; 54 (02) 1482-1499
  • 7 Cao F, Yang XF, Liu WG. et al. Elevation of neuron-specific enolase and S-100β protein level in experimental acute spinal cord injury. J Clin Neurosci 2008; 15 (05) 541-544
  • 8 Qiu Z, Wang F, Hong Y. et al. Clinical predictors of neurological outcome within 72 h after traumatic cervical spinal cord injury. Sci Rep 2016; 6: 38909
  • 9 Wolf H, Krall C, Pajenda G. et al. Alterations of the biomarker S-100B and NSE in patients with acute vertebral spine fractures. Spine J 2014; 14 (12) 2918-2922
  • 10 Gazzolo D, Michetti F. Perinatal S100B protein assessment in human unconventional biological fluids: a minireview and new perspectives. Cardiovasc Psychiatry Neurol 2010; 703563
  • 11 Kwon BK, Casha S, Hurlbert RJ, Yong VW. Inflammatory and structural biomarkers in acute traumatic spinal cord injury. Clin Chem Lab Med 2011; 49 (03) 425-433
  • 12 Hajduková L, Sobek O, Prchalová D. et al. Biomarkers of brain damage: S100B and NSE concentrations in cerebrospinal fluid—a normative study. BioMed Res Int 2015; 379071
  • 13 Portela LV, Tort AB, Schaf DV. et al. The serum S100B concentration is age dependent. Clin Chem 2002; 48 (6.1): 950-952
  • 14 Lee SJ, Kim CW, Lee KJ. et al. Elevated serum S100B levels in acute spinal fracture without head injury. Emerg Med J 2010; 27 (03) 209-212
  • 15 Faridaalee G, Keyghobadi Khajeh F. Serum and cerebrospinal fluid levels of S-100β is a biomarker for spinal cord injury; a systematic review and meta-analysis. Arch Acad Emerg Med 2019; 7 (01) e19